- JP-listed companies
- OncoTherapy Science, Inc.
- Income statement
OncoTherapy Science, Inc. (4564) Income statement
Market cap
¥6.4B
P/E ratio
OncoTherapy Science develops cancer treatments using genetic research, including targeted drugs, immunotherapies, and precision medicine testing for personalized cancer care.
| 2012/03 | 2013/03 | 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Revenue | 6,224 | 3,277 | 1,018 | 770 | 267 | 287 | 211 | 281 | 316 | 332 | 1,154 | 1,135 | 610 | 750 |
| Revenue growth (%) | - | |||||||||||||
| Cost of revenue | - | - | - | - | - | - | - | - | 366 | 313 | 1,040 | 1,093 | 788 | 763 |
| Operating margin (%) | - | - | - | |||||||||||
| Operating expenses | - | - | - | 339 | 364 | 353 | 268 | 408 | 397 | 282 | 436 | 432 | 265 | 294 |
| Operating income | - | - | - | -1,962 | -2,981 | -3,004 | -2,989 | -2,954 | -2,190 | -1,638 | -2,053 | -1,106 | -1,121 | -798 |
| Income before tax | 1,256 | -1,114 | -3,768 | -1,940 | -2,963 | -3,009 | -2,977 | -2,959 | -2,197 | -1,639 | -2,072 | -1,133 | -1,136 | -815 |
| Pretax margin (%) | 20.2 | -34 | -370.2 | -251.9 | -1,110.2 | -1,049.5 | -1,409.3 | -1,054.6 | -694.8 | -493 | -179.6 | -99.8 | -186.3 | -108.7 |
| Provision for income taxes | - | - | - | -5 | -1 | 4 | 7 | -3 | 2 | 2 | 1 | 2 | 2 | 2 |
| Effective tax rate (%) | - | - | - | |||||||||||
| Net income | 745 | -1,050 | -3,821 | -1,318 | -2,789 | -3,002 | -2,851 | -2,935 | -2,239 | -1,562 | -2,572 | -1,119 | -1,288 | -815 |
| Net income margin (%) | ||||||||||||||
| Earnings per share | 3,476.64 | -10.23 | -28.2 | -9.09 | -18.97 | -20.42 | -19.39 | -19.9 | -13.73 | -8.86 | -13.72 | -5.81 | -6.05 | -3.12 |
| Diluted EPS | 3,097.69 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | ||||||||
| EBITDA margin (%) | - | - | - | - | - | - |